60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.130
0.00 (0.00%)
At close: Aug 21, 2026, 4:00 PM EDT
1.114
-0.016 (-1.43%)
After-hours: Aug 21, 2026, 7:39 PM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $207.90K in the quarter ending June 30, 2026, a decrease of -32.47%. This brings the company's revenue in the last twelve months to $1.21M, up 23.41% year-over-year. In the year 2025, 60 Degrees Pharmaceuticals had annual revenue of $1.41M with 106.81% growth.
Revenue (ttm)
$1.21M
Revenue Growth
+23.41%
P/S Ratio
2.47
Revenue / Employee
$404,977
Employees
3
Market Cap
3.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.41M | 727.75K | 106.81% |
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| Curis | 4.31M |
| Onconetix | 645.82K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
SXTP News
- 8 days ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results - GlobeNewsWire
- 9 days ago - 60 Degrees Pharmaceuticals Registration statement: Registration filing - Filings
- 9 days ago - 60 Degrees Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 9 days ago - 60 Degrees Pharmaceuticals Earnings release: Q2 2026 - Filings
- 23 days ago - 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 24 days ago - 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 - GlobeNewsWire
- 6 weeks ago - 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - GlobeNewsWire
- 7 weeks ago - 60 Degrees Pharmaceuticals Proxy statement: Proxy filing - Filings